source
- ASCO Highlights Barriers to Cancer Care and New Treatments Amid Memorable Pancreatic Cancer Study OvationThe annual ASCO meeting featured extensive discussion of the obstacles patients face in accessing cancer care and showcased a range of emerging therapies. STAT compiled a quick‑take newsletter tha…
- Revolution Medicines reports pancreatic cancer drug daraxonrasib extends median survival to 13.2 months in second-line studyRevolution Medicines released detailed data confirming that its experimental pancreatic cancer therapy, daraxonrasib, improved overall survival for patients with advanced disease. In the second‑lin…